CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...